Harvey R Donald
Grady Health System, Georgia Cancer Center for Excellence, Atlanta, Georgia, USA.
Pharmacotherapy. 2005 Nov;25(11 Pt 2):85S-93S. doi: 10.1592/phco.2005.25.11part2.85S.
Intravenous immunoglobulin (IGIV) originally was used as prophylactic treatment of infections in patients with primary immunodeficiency disease. Today, administration of IGIV, due in large part to its immunomodulatory activity, has expanded to include a number of other disorders. Available data suggest that the accepted indications for IGIV will continue to expand. As the number of clinical applications for this therapy grows, so will market opportunities; current preparations will be modified and improved and new products introduced. Intravenous immunoglobulin therapy has improved the lives of many patients with immune-related disorders. Future applications will ideally advance this paradigm further.
静脉注射免疫球蛋白（IGIV）最初用于原发性免疫缺陷病患者感染的预防性治疗。如今，由于其在很大程度上具有免疫调节活性，IGIV的应用范围已扩大到包括许多其他疾病。现有数据表明，IGIV公认的适应证将继续扩大。随着这种疗法临床应用数量的增加，市场机会也会增加；现有的制剂将得到改进和完善，并推出新产品。静脉注射免疫球蛋白疗法改善了许多免疫相关疾病患者的生活。理想情况下，未来的应用将进一步推进这一模式。
